Drug Trial Radar · NCT06382662
Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 29, 2024
Primary completion
Dec 30, 2024
Study completion Mar 6, 2025
Sponsor
- Lead sponsor
- Primus PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Sun Valley Arthritis Center
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Every participant will receive active study drug and one (1 )comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. There will be ( four (4) visits.
Conditions
- Cognitive Impairment
Interventions
metaxalone m640 mgDrug
A single dose of micronize metaxalone 640 mg
tizanidine 8mgDrug
A single dose of tizanidine 8 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline, Standard Deviation of Lateral Position, no TrafficTime frame: thirty minutes
- Change From Baseline, Standard Deviation of Lateral Position, Oncoming TrafficTime frame: thirty minutes
- Change From Baseline, Standard Deviation of Lateral Position, Oncoming Traffic Plus Lead VehicleTime frame: thirty minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Valley Arthritis Center
Peoria, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.